Study | Dose (mg/day) | Days of administration | Number of patients | Impact on | Overgrowth | |||||||
Aerobic GP cocci | Pseudomonas | Enterobacteria incl. E. coli | Anaerobic cocci | Lactobacillus | Bifidobacteria | Bacteroides | Clostridium | Candida | ||||
Lode et al (2001)51 | 875/125 | 7 | 12 | Increase | – | Increase | Little change | Decrease | Decrease | Little change | Decrease | |
Young & Schmidt (2004)*49 | 875/125×2 | 10 | 1 | – | – | Clusters present | – | – | Clusters present | Clusters present | Two clusters | |
Engelbrektson et al (2009)†50 | 875/?x2 | 7 | 32 | – | – | Increase | – | No trend | No trend | Increase | No trend | |
Forssten et al (2014)†48 | 875/125 | 7 | 80 | Increased | Not affected in probiotic group | Decreased in the placebo group | Decreased | |||||
Korpela et al (2016)‡31 | – | – | 142 | Slight decrease | Two fold elevated Parabacteroides | |||||||
Kabbani et al 201752 | 875/125×2 | 7 | 12 | Increase | Increased | Decreased | Decreased | Increased | Decreased | |||
Mangin et al (2012)47 | 875/125×2 | 5 | 18 | Increased | Decreased |
*This paper reported shifts in the representation of the major bacterial groups.
†Probiotic also given.
‡And penicillin V.
GP, gram positive.